
1. vaccine. 2016 apr 12;34(17):2035-43. doi: 10.1016/j.vaccine.2015.12.020. epub
2015 dec 19.

development candidate reference material adventitious virus detection in
vaccine biologicals manufacturing deep sequencing.

mee et(1), preston md(2), minor pd(3), schepelmann s(3); cs533 study
participants.

collaborators: huang x(4), nguyen j(4), wall d(4), hargrove s(4), fu t(4), xu
g(4), li l(4), cote c(5), delwart e(6), li l(6), hewlett i(7), simonyan v(7),
ragupathy v(7), alin vk(7), mermod n(8), hill c(9), ottenwälder b(10), richter
dc(10), tehrani a(10), jacqueline wl(10), cassart jp(11), letellier c(11),
vandeputte o(11), ruelle jl(11), deyati a(11), la neve f(12), modena c(12), mee
e(13), schepelmann s(13), preston m(13), minor p(13), eloit m(14), muth e(14),
lamamy a(14), jagorel f(14), cheval j(14), anscombe c(15), misra r(15),
wooldridge d(15), gharbia s(15), rose g(15), ng sh(16), charlebois rl(16),
gisonni-lex l(16), mallet l(16), dorange f(17), chiu c(18), naccache s(18),
kellam p(19), van der hoek l(19), cotten m(19), mitchell c(20), baier bs(20), sun
w(20), malicki hd(20).

author information: 
(1)division virology, national institute biological standards control,
medicines healthcare products regulatory agency, south mimms, hertfordshire
en6 3qg, united kingdom. electronic address: edward.mee@nibsc.org.
(2)division technology, development infrastructure, national institute for
biological standards control, medicines healthcare products regulatory
agency, south mimms, hertfordshire en6 3qg, united kingdom.
(3)division virology, national institute biological standards control,
medicines healthcare products regulatory agency, south mimms, hertfordshire
en6 3qg, united kingdom.
(4)advance biosciences, houston, tx, united states.
(5)bioreliance, rockville, md, united states.
(6)blood systems research institute, san francisco, ca, united states; university
of california, san francisco, united states.
(7)center biologics evaluation research/food drug administration,
bethesda, md, united states.
(8)institute biotechnology, university lausanne, switzerland.
(9)charles river biopharmaceutical services, erkrath, germany.
(10)eurofins genomics, ebersberg, germany.
(11)gsk vaccines, rixensart, belgium.
(12)merck-serono, colleretto giacosa, italy.
(13)national institute biological standards control, south mimms,
hertfordshire, united kingdom.
(14)pathoquest, paris, france.
(15)public health england, colindale, london, united kingdom.
(16)sanofi pasteur ltd., toronto, ontario, canada.
(17)texcell, evry, france.
(18)university california, san francisco, united states.
(19)wellcome trust sanger institute, cambridge, united kingdom.
(20)wuxiapptecinc, philadelphia, pa, united states.

background: unbiased deep sequencing offers potential improved
adventitious virus screening vaccines biotherapeutics. successful
implementation assays require appropriate control materials to
confirm assay performance sensitivity.
methods: common reference material containing 25 target viruses produced
and 16 laboratories invited process using preferred adventitious
virus detection assay.
results: fifteen laboratories returned results, obtained using wide range of
wet-lab informatics methods. six 25 target viruses detected all
laboratories, remaining viruses detected 4-14 laboratories. six
non-target viruses detected three laboratories.
conclusion: study demonstrated wide range methods currently
used adventitious virus detection screening biological products deep
sequencing yield significantly different results. this
underscores need common reference materials ensure satisfactory assay 
performance enable comparisons laboratories.

copyright © 2015 authors. published elsevier ltd.. rights reserved.

doi: 10.1016/j.vaccine.2015.12.020 
pmcid: pmc4823300
pmid: 26709640  [indexed medline]

